pocketful logo
Choksi Laboratories Ltd logo

Choksi Laboratories Ltd

NSE: BSE: 526546

₹110.95

(0.86%)

Fri, 06 Mar 2026, 08:49 pm

mtf coin illustrationMTF 5x

Choksi Laboratories Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    62.44

  • Net Profit

    1.52

  • P/B

    3.55

  • Sector P/E

    76.37

  • P/E

    54.86

  • EV/EBITDA

    9.87

  • Debt/Equity (Industry)

    0.58

  • Interest Cover (Industry)

    3.46

  • ROCE (Industry)

    5.19

  • RONW (Industry)

    4.39

  • ROE

    6.63

  • ROCE

    8.89

  • Debt/Equity

    1.31

  • EPS (TTM)

    2.29

  • Dividend Yield

    0

  • Book Value

    35.17

  • Interest Cover

    1.79

Analysis

all

thumbs up icon

Pros

  • Choksi Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Choksi Laboratories has been profitable on average in the past, therefore cash runway is not a concern.
  • Choksi Laboratories has been profitable on average in the past, therefore cash runway is not a concern.
  • Debt is well covered by operating cash flow (30.8%, greater than 20% of total debt).
  • The average tenure for the Choksi Laboratories board of directors is over 10 years, this suggests they are a seasoned and experienced board.
thumbs up icon

Cons

  • Unable to evaluate Choksi Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Choksi Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Debt is not covered by short term assets, assets are 0.7x debt.
  • Choksi Laboratories's long term commitments exceed its cash and other short term assets.
  • The level of debt compared to net worth has increased over the past 5 years (44% vs 97.7% today).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters31.4831.4831.4831.4831.48
FII5.695.694.311.940
DII00000
Public62.8362.8364.2166.5868.52
Government00000

Read More

Technical Analysis

RSI

37.32

MACD

-5.60

50 DMA

114.96

200 DMA

154.95

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic171.95142.75126.85113.5597.6584.3555.15
Fibonacci142.75131.60124.70113.55102.4095.5084.35
Camarilla118.98116.30113.63113.55108.27105.60102.92

Pivots Level: Classic

R3

+58.40

171.95

R2

+29.20

142.75

R1

+13.30

126.85

113.55
113.55
Pivot Point
LTP: 96.05

S1

-15.90

97.65

S2

-29.20

84.35

S3

-58.40

55.15

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    101.97

  • 20-EMA

    106.96

  • 30-EMA

    110.01

  • 50-EMA

    115.40

  • 100-EMA

    127.62

  • 200-EMA

    134.85

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
07 Feb 2026board-meetingsQuarterly Results, Change in Directors
14 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
22 Aug 2025agm
14 Aug 2024agm
14 Aug 2023agm
13 Aug 2022agm
13 Aug 2021agm

Read More

Peer Comparison

Choksi Laboratories Ltd logo

Choksi Laboratories Ltd

Max Healthcare Institute Ltd logo

Max Healthcare Institute Ltd

Narayana Hrudayalaya Ltd logo

Narayana Hrudayalaya Ltd

Aster DM Healthcare Ltd logo

Aster DM Healthcare Ltd

Apollo Hospitals Enterprise Ltd logo

Apollo Hospitals Enterprise Ltd

Fortis Healthcare Ltd logo

Fortis Healthcare Ltd

Read More

Choksi Laboratories Ltd About

Choksi Laboratories is engaged in the sole segment of Analysis and Testing.

Industry

Miscellaneous

Founded

1993

Headquarters

CEO

Sunil Choksi

Employees

Contact

Website icon

Website

http://www.choksilab.com

Email icon

Email

compliance_officer@choksilab.com, indore@choksilab

Phone icon

Phone

Location icon

Location

Survey no 9/1 Gram Kumerdi, Near to Tulshiyana Indl Park, Indore, Madhya Pradesh, 452010

Read More

Choksi Laboratories Ltd Company History

YearHistory
1982
  • The promoters of the Company established partnership and proprietary firms in the testing and analysis business.
1993
  • The Company was incorporated with the main object to act as analyser and examiner of pharmaceuticals, medicines, and drugs, and to provide testing facilities for various items.
2014
  • The Board approved the incorporation of a wholly owned foreign subsidiary of the Company in the United States of America.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
ESSENCE DEALMARK PRIVATE LIMITEDSell40457142.2806 Nov 2025
NEXUS GLOBAL OPPORTUNITIES FUNDBuy5000021513 Aug 2025
NEXUS GLOBAL OPPORTUNITIES FUNDBuy40000197.9501 Jul 2025
LOVLESH JAINSell54451130.0204 Jun 2025
NEXUS GLOBAL OPPORTUNITIES FUNDBuy5000013004 Jun 2025
PSR WEALTH ADVISORS LLPSell4477611807 May 2025
ALANKIT IMAGINATIONS LIMITEDBuy4450011807 May 2025
ALANKIT IMAGINATIONS LIMITEDBuy40000121.8106 May 2025
PARDEEP KUMAR AGGARWALSell71000121.2806 May 2025
NEXUS GLOBAL OPPORTUNITIES FUNDBuy40000120.8206 May 2025

Read More

Choksi Laboratories Ltd News

Choksi Labs Reconstitutes Board Committees

Choksi Laboratories Limited reconstituted its Audit, Nomination and Remuneration, and Stakeholders' Relationship Committees following director changes on February 07, 2026.

07 Feb 2026

stocks

Choksi Labs Q3FY26 Results & Board Changes

Choksi Laboratories reports Q3FY26 financial results with revenue of ₹1,082.47 lakhs. Company appoints Ritik Pavecha as Independent Director while Meenaxi Patidar resigns from board.

07 Feb 2026

co actions results

Choksi Labs Independent Director Resigns

Mrs. Meenaxi Patidar resigned as Independent Director of Choksi Laboratories Limited effective January 09, 2026, citing preoccupation and personal commitments. She also ceased her roles in key board committees.

10 Jan 2026

stocks

Simran Farms Limited Publishes Quarterly and Half-Year Financial Results

Simran Farms Limited published extracts of its financial results for the quarter and half-year ended September 30, 2025, in newspapers Free Press Indore and Choutha Sansaar on November 16, 2025. The company filed the compliance under SEBI listing regulations with BSE Limited, fulfilling its regulatory disclosure obligations.

17 Nov 2025

earnings

Choksi Laboratories Reports Quarterly Financial Results for September 2025

Choksi Laboratories Limited submitted unaudited financial results for the quarter and half year ended September 30, 2025, showing revenue from operations of ₹1,111.71 lakhs for the quarter and ₹2,235.90 lakhs for the half year. The analytical testing and calibration laboratory company reported profit before tax of ₹56.25 lakhs for the quarter and ₹118.99 lakhs for the half year, with results approved by the Audit Committee and Board of Directors.

14 Nov 2025

earnings

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800